Lubos Marek, PhD
Pharmaceutical and Biotech Executive | Committed Growth Hacker and Corporate Transformation Champion | Accelerating Value Creation during Adverse Periods
Personalized cancer immunotherapy for aggressive hypoxic tumors with blockbuster potential. Our Target Mechanism For Treating Hypoxic Tumors: Carbonic Anhydrase IX (CA IX). Our Mission: - to fill the gap in treatment of oncology diseases with poor prognosis, - to increase survival rate and bring hope to patients who have undergone different types of therapies without success, - to deliver novel therapeutics that match the principle of personalized medicine which will help patients to improve the quality of their lives. Crunchbase https://www.crunchbase.com/organization/mabpro-therapeutics
